Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.59 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.59 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.59 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.59 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | MME | P08473 | 6/20 | 0.57 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.52 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.52 |
| ▸ | ACE | P12821 | 3/20 | 0.51 |
| ▸ | CPA1 | P15085 | 3/20 | 0.51 |
| ▸ | ACE2 | Q9BYF1 | 3/20 | 0.51 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9830046 | 1.00 | CHRNB2 (0.59) | CHRNB2CHRNB4CHRNA3CHRNA4GRIA1 | |
| SCHEMBL12434361 | 1.00 | CHRNB2 (0.59) | CHRNB2CHRNB4CHRNA3CHRNA4GRIA1 | |
| SCHEMBL6375698 | 0.99 | LMNA (0.59) | CHRNB2CHRNB4CHRNA3CHRNA4GRIA1 | |
| SCHEMBL7778087 | 0.89 | LMNA (0.71) | LMNATDP1MMEACECPA1 | |
| SCHEMBL4889588 | 0.89 | LMNA (0.71) | LMNATDP1MMEACECPA1 | |
| SCHEMBL16452917 | 0.89 | LMNA (0.71) | LMNATDP1MMEACECPA1 | |
| SCHEMBL9716670 | 0.89 | LMNA (0.71) | LMNATDP1MMEACECPA1 | |
| SCHEMBL16452933 | 0.88 | LMNA (0.56) | CHRNB2CHRNB4CHRNA3CHRNA4GRIA1 | |
| SCHEMBL16452945 | 0.88 | LMNA (0.56) | CHRNB2CHRNB4CHRNA3CHRNA4GRIA1 | |
| SCHEMBL16452943 | 0.88 | LMNA (0.56) | LMNATDP1MMEACECPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040062773-A1 | Compositions for the delivery of antigens | EMISPHERE TECHNOLOGIES INC. | 2004-04-01 | — | — | US | claimed |
| EP-0784469-B1 | COMPOSITIONS FOR THE DELIVERY OF ANTIGENS | EMISPHERE TECH INC (US) | 2004-03-24 | — | — | EP | claimed |
| US-6610329-B2 | Using acylated amino acid as carrier | EMISPHERE TECHNOLOGIES INC. | 2003-08-26 | — | — | US | claimed |
| US-20020001591-A1 | Compositions for the delivery of antigens | EMISPHERE TECHNOLOGIES, INC. | 2002-01-03 | — | — | US | claimed |
| US-5958457-A | MIXTURES OF ANTIGENS WITH ADJUVANTS AND ACYLATED AMINO ACIDS OR SALTS, POLYMERS OR SULFONATED AMINO ACIDS | EMISPHERE TECHNOLOGIES, INC. (US) | 1999-09-28 | — | — | US | claimed |
| EP-0784469-A4 | COMPOSITIONS FOR THE DELIVERY OF ANTIGENS | EMISPHERE TECH INC (US) | 1999-03-24 | — | — | EP | claimed |
| EP-0784469-A1 | COMPOSITIONS FOR THE DELIVERY OF ANTIGENS | Emisphere Technologies, Inc. (US) | 1997-07-23 | — | — | EP | claimed |
| WO-1996012474-A1 | COMPOSITIONS FOR THE DELIVERY OF ANTIGENS | EMISPHERE TECHNOLOGIES, INC. (US) | 1996-05-02 | — | — | WO | claimed |
| EP-2409569-B1 | Method for administering GLP-1 molecules | EMISPHERE TECH INC (US) | 2017-08-16 | — | — | EP | disclosed |
| EP-1478233-B1 | METHOD FOR ADMINISTERING GLP-1 MOLECULES | EMISPHERE TECH INC (US) | 2016-11-09 | — | — | EP | disclosed |
| US-20150202296-A1 | METHOD FOR ADMINISTERING GLP-1 MOLECULES | NOVO NORDISK NORTH AMERICA OPERATIONS A/S (DK) | 2015-07-23 | — | — | US | disclosed |
| US-20150202296-A1 | METHOD FOR ADMINISTERING GLP-1 MOLECULES | NOVO NORDISK NORTH AMERICA OPERATIONS A/S (DK) | 2015-07-23 | — | — | US | disclosed |
| US-8492330-B2 | Formulation comprising GLP-1 | EMISPHERE TECHNOLOGIES, INC. (US) | 2013-07-23 | — | — | US | disclosed |
| US-8492330-B2 | Formulation comprising GLP-1 | EMISPHERE TECHNOLOGIES, INC. (US) | 2013-07-23 | — | — | US | disclosed |
| EP-0758843-A1 | MODIFIED AMINO ACIDS FOR DRUG DELIVERY | Emisphere Technologies, Inc. (US) | 1997-02-26 | — | — | EP | disclosed |
| WO-1996021464-A9 | COMPOSITIONS FOR THE DELIVERY OF ANTIGENS | — | 1996-11-14 | — | — | WO | disclosed |
| WO-1995028838-A1 | MODIFIED AMINO ACIDS FOR DRUG DELIVERY | EMISPHERE TECHNOLOGIES, INC. (US) | 1995-11-02 | — | — | WO | disclosed |
| EP-0226304-B1 | COMPOSITION CONTAINING A PENEM OR CARBAPENEM ANTIBIOTIC | SANKYO COMPANY LIMITED (JP) | 1991-08-28 | — | — | EP | disclosed |
| US-4757066-A | Reduces renal toxicity | SANKYO COMPANY LIMITED (JP) | 1988-07-12 | — | — | US | disclosed |
| EP-0226304-A1 | Composition containing a penem or carbapenem antibiotic | SANKYO COMPANY LIMITED (JP) | 1987-06-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020001591-A1 | Compositions for the delivery of antigens | CD47, CD74, LY96 | CHRNB2 2707/4885CHRNB4 3455/4885CHRNA3 3354/4885 |
| US-20040062773-A1 | Compositions for the delivery of antigens | CD47, CD74, LY96 | CHRNB2 2707/4885CHRNB4 3455/4885CHRNA3 3354/4885 |
| US-20150202296-A1 | METHOD FOR ADMINISTERING GLP-1 MOLECULES | GLP1R, GIPR, GPR119 | CHRNB2 978/4885CHRNB4 1011/4885CHRNA3 1112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.